^
    20h
    SOUNDTRACK-D2: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (clinicaltrials.gov)
    P3, N=420, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    doxorubicin hydrochloride • cyclophosphamide • surovatamig (AZD0486)
    21h
    A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients (clinicaltrials.gov)
    P1, N=28, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • bendamustine • melphalan
    23h
    Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy (clinicaltrials.gov)
    P2, N=27, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2026 --> Jan 2027 | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    JAK1 (Janus Kinase 1) • CRP (C-reactive protein)
    |
    Yescarta (axicabtagene ciloleucel) • itacitinib (INCB039110)
    1d
    Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma (clinicaltrials.gov)
    P3, N=99, Recruiting, The Affiliated People's Hospital of Ningbo University | Trial completion date: Dec 2026 --> Aug 2026 | Trial primary completion date: Dec 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV
    1d
    BELLWAVE-003: Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) (clinicaltrials.gov)
    P2, N=490, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2027 --> Jan 2029 | Trial primary completion date: Mar 2027 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • CD4 (CD4 Molecule)
    |
    TP53 mutation • Chr t(11;14)
    |
    nemtabrutinib (MK-1026)
    1d
    Primary non-Hodgkin lymphoma in the muscle of left lower extremity: a case report and literature review. (PubMed, Front Oncol)
    CD5+ diffuse large B-cell lymphoma (DLBCL) is aggressive, and Rituximab-Cyclophosphamide Hydroxydaunorubicin Vincristine Prednisone (R-CHOP) combined with radiotherapy is recommended, but prognosis is affected by age, Lactate Dehydrogenase (LDH) levels, and molecular characteristics such as TP53 mutations. Radiotherapy and chemotherapy are the first choice for treatment. It is very important to formulate a reasonable treatment plan according to the results of pathology and molecular analysis.
    Journal
    |
    TP53 (Tumor protein P53) • CD5 (CD5 Molecule)
    |
    TP53 mutation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone
    1d
    Bioinspired Design of Single-Atom Micellar Nanozymes Facilitates Internal Environment-Driven Synergistic Therapy against Lymphoma. (PubMed, ACS Appl Mater Interfaces)
    Extensive in vitro and in vivo studies demonstrated the micelles' potent catalytic activity, significant inhibition of lymphoma progression, and strong antimetastatic effects. Notably, the use of FDA-approved PLGA and clinically established DOTA chelation highlights the strong translational potential of this platform for future clinical applications.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    2d
    Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma (clinicaltrials.gov)
    P=N/A, N=144, Recruiting, University Health Network, Toronto | N=80 --> 144 | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    2d
    KSV01 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, TCRx Therapeutics Co.Ltd
    New P1 trial
    2d
    WF-1804CD: Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors (clinicaltrials.gov)
    P=N/A, N=600, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed
    Trial completion
    2d
    Acquired MYC rearrangement potentially associated with ibrutinib resistance in mantle cell lymphoma. (PubMed, Virchows Arch)
    In conclusion, our findings suggest that c-Myc overexpression and MYC rearrangement are associated with ibrutinib resistance in MCL. Detecting MYC rearrangement in selected MCL cases could be critical for optimizing treatment strategies and improving patient outcomes.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Imbruvica (ibrutinib)
    2d
    A Novel Prognostic Model for Primary CNS Lymphoma Incorporating Clinico-Laboratory Parameters. (PubMed, Neuro Oncol)
    The ABLE risk-stratification model can effectively differentiate prognostic subgroups in patients with PCNSL.
    Journal
    |
    B2M (Beta-2-microglobulin)
    |
    methotrexate • methotrexate IV